PRESS RELEASE published on 06/05/2024 at 07:30, 5 months 4 days ago OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant OSE Immunotherapeutics and Nantes University Hospital present positive Phase 1/2 study evaluating FR104/VEL-101 immunotherapy in renal transplant at American Transplant Congress 2024 Immunotherapy Phase 1/2 Study OSE Immunotherapeutics Nantes University Hospital Renal Transplant
PRESS RELEASE published on 06/05/2024 at 07:30, 5 months 4 days ago OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale OSE Immunotherapeutics et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l'essai clinique de Phase 1/2 évaluant l'immunothérapie FR104/VEL-101 en transplantation rénale au congrès 'American Transplant Congress' 2024 Essai Clinique OSE Immunotherapeutics Transplantation Rénale FR104/VEL-101 Centre Hospitalier Universitaire De Nantes
BRIEF published on 05/22/2024 at 07:35, 5 months 18 days ago OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour de nouveaux traitements Collaboration Immunothérapie Cancer Cardio-rénal-métabolique
BRIEF published on 05/22/2024 at 07:35, 5 months 18 days ago OSE Immunotherapeutics and Boehringer Ingelheim Expand Collaboration for Novel Treatments Collaboration Immunotherapy Cancer Cardio-renal-metabolic
PRESS RELEASE published on 05/22/2024 at 07:30, 5 months 18 days ago OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et métaboliques OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements innovants dans le cancer et les maladies CVRM. Deux nouveaux projets first-in-class annoncés renforcent le portefeuille de Boehringer Ingelheim Cancer Boehringer Ingelheim OSE Immunotherapeutics Traitements Innovants Maladies CVRM
PRESS RELEASE published on 05/22/2024 at 07:30, 5 months 18 days ago OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases OSE Immunotherapeutics and Boehringer Ingelheim expand partnership to develop first-in-class therapies for cancer and cardio-renal-metabolic diseases, aiming to address unmet patient needs Partnership Cancer Boehringer Ingelheim OSE Immunotherapeutics First-in-class Treatments
PRESS RELEASE published on 05/26/2023 at 08:15, 1 year 5 months ago OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23
Published on 11/09/2024 at 16:30, 8 hours 18 minutes ago New to the Street Premieres Episode 611 on Bloomberg Television Tonight at 6:30 PM EST, Featuring Zapp Electric Vehicles, OriginClea and PillSafe
Published on 11/09/2024 at 04:00, 20 hours 48 minutes ago Freedom Holding Corp. Reports Second Quarter Fiscal Year 2025 Financial Results
Published on 11/08/2024 at 23:05, 1 day 1 hour ago Murchison Minerals Announces Non-Brokered Private Placement
Published on 11/08/2024 at 20:15, 1 day 4 hours ago Able View Global Inc. Raises USD$4 Million from Convertible Notes Financing to Propel Growth
Published on 11/08/2024 at 18:35, 1 day 6 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/08/2024 at 18:20, 1 day 6 hours ago ENCAVIS achieves results in the first three quarters of 2024 below the figures for the same period of the previous year due to unforeseeable events and adjusts guidance for the current financial year
Published on 11/08/2024 at 18:02, 1 day 6 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/08/2024 at 18:00, 1 day 6 hours ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 11/08/2024 at 18:00, 1 day 6 hours ago Covivio - Information on total number of voting rights and share capital
Published on 11/08/2024 at 17:52, 1 day 6 hours ago Total number of voting rights and shares making up the share capital at October 31, 2024
Published on 11/08/2024 at 17:45, 1 day 7 hours ago CHARGEURS - Voting rights monthly statement as of October 31st, 2024